Latest News

  • Industry Cooperation

  • Publish Date：2026-07-15
NYCU Joins Taiwan Regenerative Medicine Alliance to Advance Next-Generation Healthcare
From left: Hank Huang, Vice President of the Office of Industrial-Academia Co-creation, NYCU; Chun-Hsuan Ho, Chairman of the Taiwan Regenerative Medicine Alliance; Chi-Hung Lin, President of NYCU; Chi-Wei Yu, Deputy Director of Research Division VII, TIER; and Tzu-Hao Cheng, Senior Vice President of NYCU. (Photo credit: Taiwan Regenerative Medicine Alliance)
From left: Hank Huang, Vice President of the Office of Industrial-Academia Co-creation, NYCU; Chun-Hsuan Ho, Chairman of the Taiwan Regenerative Medicine Alliance; Chi-Hung Lin, President of NYCU; Chi-Wei Yu, Deputy Director of Research Division VII, TIER; and Tzu-Hao Cheng, Senior Vice President of NYCU.
(Photo credit: Taiwan Regenerative Medicine Alliance)
 
Edited by Chance Lai
______
Taiwan is strengthening its regenerative medicine ecosystem through a new partnership between the Taiwan Regenerative Medicine Alliance (TRMA) and National Yang Ming Chiao Tung University (NYCU), bringing together expertise in biomedical engineering, artificial intelligence, clinical medicine, and semiconductor technologies to accelerate next-generation healthcare innovation.

The two organizations recently signed a memorandum of understanding (MOU), marking a new phase of collaboration across academia, industry, research institutions, and healthcare providers. Witnessed by the Taiwan Institute of Economic Research (TIER), the agreement aims to build a more integrated innovation ecosystem that translates scientific discoveries into clinical and industrial applications while enhancing Taiwan’s international competitiveness.

Integrating Engineering and Medicine

Since the 2021 merger of National Yang-Ming University and National Chiao Tung University, NYCU has combined its strengths in medicine, life sciences, engineering, and information and communication technologies to develop innovative healthcare solutions.

NYCU President Chi-Hung Lin said the university continues to leverage this interdisciplinary foundation to advance smart healthcare, biomedical engineering, and regenerative medicine.

“By integrating engineering, medicine, and digital technologies, NYCU is creating new opportunities for innovation in regenerative medicine,” Lin said. “Through collaboration with industry and research partners, we hope to accelerate technological translation, cultivate future talent, and strengthen Taiwan’s global competitiveness.”

As one of the alliance’s key academic partners, NYCU will contribute expertise in BioICT biomedical chips, AI-enabled healthcare, automated stem cell manufacturing, and translational biomedical research.

Among its flagship technologies is a semiconductor-based BioICT platform that integrates microfluidics, capacitive sensing, temperature control, and microscopic imaging onto a single chip. Designed using Taiwan’s semiconductor manufacturing technologies, the platform enables automated cell quality analysis while improving production efficiency and reducing manufacturing costs.

The technology has already been adopted by the CiRA Foundation at Kyoto University in Japan for automated quality assessment of induced pluripotent stem (iPS) cells, highlighting its potential for international regenerative medicine applications.

Building the Next Generation of Smart Biobanking

A major focus of the partnership will be developing a Next-Generation Intelligent Biobank (NGIB) capable of storing up to 500,000 biological samples.

Unlike conventional biobanks that rely heavily on manual operation, the proposed platform combines fully automated ultra-low-temperature storage with NYCU’s proprietary BioICT Quality Control (QC) Chip and AI-powered predictive maintenance technologies. The system is expected to improve storage efficiency, quality management, and long-term reliability while transforming Taiwan’s semiconductor expertise into advanced biomedical infrastructure for regenerative medicine.

The collaboration will also expand AI-assisted drug discovery through NYCU’s College of Pharmaceutical Sciences, where researchers use biomedical databases and machine learning algorithms to predict interactions between therapeutic compounds and biological targets, helping shorten the early stages of drug development.

In parallel, NYCU Hospital will work toward developing clinical operations that align with international ISO certification and PIC/S Good Manufacturing Practice (GMP) standards, laying the foundation for future international collaboration in regenerative medicine.

Bringing Semiconductor Innovation to Regenerative Medicine

One of NYCU’s key contributions to the alliance will be its semiconductor-based biomedical chip technologies.

Developed using Taiwan Semiconductor Manufacturing Company (TSMC)’s standard semiconductor fabrication process, the BioICT platform integrates microfluidics, capacitive sensing, temperature control, and microscopic imaging into a single chip. The technology enables automated cell quality analysis while improving manufacturing efficiency and reducing production costs.



The platform has already been adopted by the CiRA Foundation at Kyoto University in Japan for automated quality assessment of induced pluripotent stem (iPS) cells, demonstrating its potential for international regenerative medicine applications.

Developing Next-Generation Smart Biobanking

The collaboration will also focus on developing a Next-Generation Intelligent Biobank (NGIB) capable of storing up to 500,000 biological samples.

The system will combine fully automated ultra-low-temperature cell storage with NYCU’s proprietary BioICT Quality Control (QC) Chip and AI-powered predictive maintenance technologies.

By reducing reliance on manual handling and improving storage standardization, the platform is expected to enhance the safety, efficiency, and scalability of cell preservation while translating Taiwan’s semiconductor precision manufacturing capabilities into advanced biomedical infrastructure.

Accelerating AI-Driven Drug Discovery and Clinical Translation

NYCU’s College of Pharmaceutical Sciences will contribute AI-assisted drug discovery technologies that combine large-scale biomedical databases with machine learning algorithms to predict interactions between therapeutic compounds and biological targets, helping shorten early-stage drug development.

The partnership also supports the development of international-standard clinical infrastructure at NYCU Hospital, with the long-term goal of achieving ISO certification and PIC/S Good Manufacturing Practice (GMP) compliance for regenerative medicine, positioning the hospital as a potential hub for future Taiwan-Japan clinical collaboration.

Training the Next Generation of Regenerative Medicine Professionals

Beyond research collaboration, the alliance and NYCU plan to establish a new academic program in regenerative medicine and cell engineering to cultivate the next generation of industry professionals.

The curriculum will include certification courses, advanced technical training, and executive education programs designed to prepare professionals for international standards such as ISO 17034, ISO 20387, and PIC/S GMP requirements for clinical operations and quality management.

Lin said the partnership extends beyond developing next-generation cell therapies and automated manufacturing technologies. “Our goal is also to build an ecosystem that connects academia and industry while cultivating the highly skilled workforce needed to support the future growth of regenerative medicine,” he said.

The TIER described the agreement as an important milestone for Taiwan’s regenerative medicine sector. The institute said. “By strengthening collaboration among academia, industry, government, and research organizations, Taiwan will be better positioned to expand its strategic role in the global regenerative medicine economy.”

Developing Future Talent

Lin said the collaboration represents more than a research partnership. “Our goal is not only to develop next-generation cell therapies and automated manufacturing technologies, but also to build an ecosystem that connects academia and industry while preparing the talent needed to support the future growth of regenerative medicine,” he said.

NYCU and the alliance plan to establish a new academic program in regenerative medicine and cell engineering, accompanied by professional training programs ranging from foundational certification courses to advanced technical and management education. The initiative aims to prepare professionals capable of meeting international standards, including ISO 17034, ISO 20387, and PIC/S GMP requirements for regenerative medicine and cell therapy.

For NYCU, the partnership reflects the university’s commitment to translating interdisciplinary research into real-world healthcare solutions. By combining expertise in medicine, engineering, artificial intelligence, and semiconductor technologies, the university aims to help shape the next generation of regenerative medicine in Taiwan and beyond.
文圖/台灣再生醫療聯盟
編譯/國際宣傳辦公室 

台灣再生醫療聯盟與國立陽明交通大學今日正式簽署合作備忘錄MOU，標誌著我國再生醫療產業邁入「產官學研跨界整合、立足台灣、協同日新、邁向國際」的新階段。台灣經濟研究院作為聯盟策略倡議者，全程見證此一合作。陽明交通大學將以其BioICT生醫晶片、AI智慧醫療、幹細胞自動化製程等領域的研發能量，成為聯盟重要的學研合作夥伴。

台灣再生醫療聯盟整合了國家級產官學科研機構，以及極光智聯、芮康生物科技股份有限公司等產業夥伴，此次陽明交大的正式加入，讓聯盟形成從基礎研究、技術開發、臨床驗證到商業應用的完整產業合作鏈。

陽明交大林奇宏校長表示，陽明大學與交通大學於2021年合校為「國立陽明交通大學」，結合資通訊科技與生醫專長，推動智慧醫療與生醫科技發展，並期望透過強強聯手提升國際競爭力，發揮一加一大於二的綜效。校方長期投入資源於半導體生醫晶片研發，其開發之晶片整合微流道運算、電容感測、溫度控制與顯微影像功能，採用台積電標準半導體製程製作，有助於提升製造效率及降低生產成本。此技術獲得國際再生醫學機構——日本京都大學CiRA基金會採用，應用於iPS細胞品質自動化檢測。

聯盟將借重陽明交大在整合生物醫學與創新工程的領先地位，共同發展符合再生醫療特性之「次世代智慧生物銀行 NGIB」，以50萬人規模為目標，建立大型自動化生物儲存系統。
 



透過極低溫全自動化快速存取細胞儲存技術，結合專屬「品質檢測晶片 BioICT QC Chip」與AI預測性維護技術開發經驗，克服傳統儲存依賴人工、空間且難以智能管理標準化之痛點，協助聯盟提升高品質細胞儲存量能，並將台灣半導體精密控制優勢轉化為高附加價值之自動化生物儲存系統，為再生醫療基礎設施發展提供技術支持。

陽明交大藥物科學院具備藥物資料庫與AI智能篩藥技術，利用大數據與AI演算法預測藥物與標靶的相互作用，縮短開發時程。透過此次合作，陽明交大附設醫院將朝向取得ISO國際認證及符合PIC/S GMP相關規範的臨床作業標準發展，並可望成為台日再生醫療合作的重要節點。

林奇宏校長表示，此次合作不僅針對下世代細胞治療藥品設計與自動化製程進行開發，更將作為產業橋梁，紮根培育下世代產業人才，提升產業競爭力。聯盟計畫將配合陽明交通大學，創新開設「再生醫療與細胞工程學分學程」與專業人才培訓計畫，包含基礎認證班、專業技術班及高階管理班，確保產業具備ISO 17034、ISO 20387及PIC/S GMP規範下的臨床操作與品管能力。

台灣經濟研究院表示：「今日的簽署代表台灣在再生醫療領域邁出重要的一步。透過產官學研的緊密結合，將有助於提升台灣在全球再生醫療經濟版圖中的戰略地位。」

Related Image(s)：
Back